SERIOUS REPORTS from over 7 percent of DOSES, mostly from ASTRAZENECA. AIFA DATA »ILMETEO.it

VACCINES: SERIOUS REPORTING from over 7 percent of DOSES, mostly from ASTRAZENECA. AIFA DATA

NEW COVID-19 surveillance REPORT releasedL’Aifa, Italian Medicines Agency, records 7% of serious reports, with a rate of 36 serious events every 100 thousand administrations. The calculation is valid for the three vaccines currently in circulation in Italy, with nearly 14 million administrations. In detail, for AstraZeneca in less than a month there were 11 cases of thrombosis, with 4 deaths.

L’Aifa has reported 46,237 reports out of a total of 9.068.349 doses administered, of which the 92.7% refer to non-serious situations, which resolves completely, such as injection site pain, fever, asthenia / fatigue, muscle aches. The serious ones correspond to 7.1% of the total, with a rate of 36 events per 100 thousand doses administered, regardless of the type of vaccine, the dose (first or second) and the possible causal role of vaccination.

The data emerge from the relationship surveillance COVID-19 (WHO the report completo) and consider the period between December 27, 2020 and March 26, 2021 for the three vaccines in use in the current vaccination campaign.
Most of the communications are related to the Comirnaty serum (Pfizer, 81%), so far the most used with 68% of doses administered. There was a 17% increase for the Vaxzevria vaccine (AstraZeneca) following the increase in its use (+ 27%). Those relating to serum Modern instead represent the 2% of the total and are proportional to the more limited number of doses administered (5%). The reported events mainly occur on the same day of vaccination or the day after in 87% of cases.

A focus was dedicated to thromboembolic cases after the inoculation of AstraZeneca, the ones that are most worrying. Have occurred, within 2 weeks of vaccination, of cases a lot rare of associated thrombi low blood platelet levels.
The investigation at national level of these reports is conducted with the support of a “Working Group for the Evaluation of Thrombotic Risks from COVID Vaccines”, made up of some of the leading national experts in thrombosis and hemostasis. Adverse events not known are subject to continuous investigation at national and European level.

– .